LLY Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Eli Lilly (LLY) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the company demonstrates strong financial performance and positive catalysts like FDA approvals and promising drug trials, insider selling and bearish retail sentiment, combined with competition in the weight-loss drug market, suggest waiting for more clarity post-Q1 earnings on April 30, 2026. The current pre-market price of $905.88 is below key resistance levels, but no strong technical or proprietary trading signals indicate an immediate buying opportunity.
The stock shows bullish moving averages (SMA_5 > SMA_20 > SMA_200), and the MACD histogram is positive at 1.778, indicating a bullish trend. However, RSI_6 at 32.31 is neutral, and the stock is trading near the support level of $898.418, suggesting limited upside in the short term.
FDA approval of Foundayo, a weight-loss drug, positions Eli Lilly to compete strongly in the obesity market.
Positive trial results for Foundayo showing significant cardiovascular and mortality benefits.
Strong financial performance in Q4 2025, with revenue up 42.56% YoY and EPS up 51.43% YoY.
Insider selling has increased significantly, up 4519.16% over the last month.
Retail investor sentiment remains bearish due to competition in the weight-loss drug market.
HSBC downgraded the stock, citing elevated expectations for the obesity market and potential price competition.
Eli Lilly reported strong financials in Q4 2025, with revenue increasing by 42.56% YoY to $19.29 billion, net income up 50.52% YoY to $6.64 billion, and EPS up 51.43% YoY to $7.39. Gross margin also improved slightly to 82.52%.
Analyst sentiment is generally positive, with multiple Buy and Overweight ratings and price targets ranging from $1,250 to $1,327. However, HSBC downgraded the stock to Reduce with a price target of $850, citing concerns about the obesity market's growth potential and price competition.
